Plus, news about Ipsen, Exelixis, Innovent, Codexis, Crosswalk Therapeutics and J&J:
Yuhan licenses prostate cancer drug: The biotech will pay Seoul-based Ubix Therapeutics $3.6 million upfront and up to $105 million in biobucks for a preclinical androgen receptor degrader known as UBX-103. — Kyle LaHucik
DRI Healthcare Trust expands royalty deal for Xenpozyme: The company will pay $13.25 million upfront and up to $32.5 million in milestones to HLS Therapeutics. The drug, which is used to treat patients with acid sphingomyelinase deficiency, is marketed by Sanofi. DRI first inked a royalty deal for Xenpozyme in 2022. — Jaimy Lee
Ipsen, Exelixis expand deal: The biotechs broadened their nearly decade-old collaboration on cancer drug Cabometyx. Updated financial terms were not disclosed. — Kyle LaHucik
Innovent touts Ph1 data for anti-Claudin drug: The company’s 6 mg dose of IBI343 achieved a 47.1% overall response rate and 88.2% disease control rate in patients with advanced gastric or gastroesophageal junction adenocarcinoma. The antibody-drug conjugate targets CLDN18.2, which is expressed in up to 80% of patients with gastric cancer. — Ayisha Sharma
Codexis sells gene therapy assets: The California biotech agreed to offload its Fabry and Pompe disease compounds to Crosswalk Therapeutics. — Kyle LaHucik
Johnson & Johnson talc settlement challenge fails: A judge last week rejected an attempt by a group of claimants to derail J&J’s talc bankruptcy settlement plan and denied a motion that would have prevented the company from filing for bankruptcy outside of New Jersey. J&J continues to pursue a $6.5 billion plan that would settle tens of thousands of ovarian cancer suits. — Nicole DeFeudis